Literature DB >> 16765529

Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer.

Orazio Caffo1, Gianni Fellin, Andrea Bolner, Franco Coccarelli, Claudio Divan, Michela Frisinghelli, Salvatore Mussari, Franco Ziglio, Gianni Malossini, Luigi Tomio, Enzo Galligioni.   

Abstract

PURPOSE: Permanent interstitial brachytherapy (IB) has become an increasingly appealing therapeutic option for localized prostate cancer (LPC) among physicians and patients because it involves short hospitalization and treatment and its postulated low degree of toxicity may reduce its impact on the patients' quality of life (QoL). The aim of this prospective study was to assess the impact of IB on the QoL of patients with LPC. METHODS AND MATERIALS: A validated self-completed questionnaire was administered to the patients before and after IB and then at yearly intervals. The items allowed the identification of seven subscales exploring physical well-being (PHY), physical autonomy (POW), psychological well-being (PSY), relational life (REL), urinary function (URI), rectal function (REC), and sexual function (SEX).
RESULTS: The assessment of the QoL of 147 patients treated between May 2000 and February 2005 revealed no relevant differences in the PHY scale scores 1 month after IB or later, and the same was true of the POW, PSY, and REL scales. Urinary function significantly worsened after IB and returned to pretreatment levels only after 3 years; the impact of the treatment on the URI scale was greater in the patients with good baseline urinary function than in those presenting more urinary symptoms before IB. Rectal and sexual functions were significantly worse only at the post-IB evaluation.
CONCLUSIONS: The results of the present study confirm that the impact of IB on the patients' QoL is low despite its transient negative effects on some function, and extend existing knowledge concerning QoL after IB.

Entities:  

Mesh:

Year:  2006        PMID: 16765529     DOI: 10.1016/j.ijrobp.2006.04.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.

Authors:  Young Dong Yu; Moon Hyung Kang; Chang Il Choi; Hyun Soo Shin; Jong Jin Oh; Dong Soo Park
Journal:  World J Urol       Date:  2016-02-11       Impact factor: 4.226

2.  Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study.

Authors:  C Giberti; L Chiono; Fabrizio Gallo; M Schenone; E Gastaldi
Journal:  World J Urol       Date:  2009-05-20       Impact factor: 4.226

Review 3.  Sexual issues in early and late stage cancer: a review.

Authors:  Sebastiano Mercadante; Valentina Vitrano; Viviana Catania
Journal:  Support Care Cancer       Date:  2010-03-18       Impact factor: 3.603

4.  Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.

Authors:  Giovanni Fellin; Maria A Mirri; Luigi Santoro; Barbara A Jereczek-Fossa; Claudio Divan; Salvatore Mussari; Francesco Ziglio; Beniamino La Face; Fernando Barbera; Michela Buglione; Laura Bandera; Barbara Ghedi; Nadia G Di Muzio; Andrea Losa; Paola Mangili; Luciano Nava; Renato Chiarlone; Nunzia Ciscognetti; Emilio Gastaldi; Federica Cattani; Ruggero Spoto; Andrea Vavassori; Francesca R Giglioli; Alessia Guarneri; Valentina Cerboneschi; Marcello Mignogna; Mauro Paoluzzi; Valentina Ravaglia; Costanza Chiumento; Stefania Clemente; Vincenzo Fusco; Roberto Santini; Marco Stefanacci; Francesco P Mangiacotti; Marco Martini; Tiziana Palloni; Giuseppe Schinaia; Grazia Lazzari; Giovanni Silvano; Stefano Magrini; Umberto Ricardi; Riccardo Santoni; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-07-07       Impact factor: 3.039

5.  A Population-based Statistical Model for Investigating Heterogeneous Intraprostatic Sensitivity to Radiation Toxicity After 125I Seed Implantation.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

6.  Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.

Authors:  Antonello Veccia; Orazio Caffo; Giovanni Fellin; Salvatore Mussari; Francesco Ziglio; Francesca Maines; Luigi Tomio; Enzo Galligioni
Journal:  Radiat Oncol       Date:  2015-06-10       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.